Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues
Humacyte was issued U.S. Patent No. 12,742,144 covering manufacturing, sterilization, storage, and shipping of Symvess and other bioengineered tissues, with protection running into 2043. The patent complements the company's existing IP family around product design, composition, and manufacture, including its LUNA200 production systems.
Key figures
- Patent number
- US 12,742,144
- Facility square feet
- 83000
- Patent protection through
- 2043
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.